For its first fiscal quarter (ending March 31), Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has reported a -100% decline in E.P.S. from $0.31 a year ago to $0.00 in the current quarter. This performance was $-0.49 short of the consensus estimate of $0.49. E.P.S. were $-0.29 for the latest four quarters through March 31 versus $0.96 for the same period a year ago — a decline of -130%.
Recent Price Action
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock rose modestly by 0.5% on 5/8/24. The stock closed at $31.30. Trading volume in this advance was normal. The stock has risen 4.0% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Supernus Pharmaceuticals has a neutral Power Rating of 47 and a slightly negative Appreciation Score of 40, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment